Is the regulator environment changing fast enough to accommodate the vast array of microbiome-based therapeutics beginning to emerge?

Looking for an experienced partner to simplify the development and manufacture of a new antibody-drug conjugate (ADC)?

Some have dismissed excitement about the microbiome as “hype,” but real results are beginning to be seen.

Nominations for The Medicine Maker 2019 will close on Friday, October 25.

David Donabedian of Axial Biotherapuetics explains the role of the microbiome in the onset of Parkinson's Disease and autism.

Joe Biden apparently dared say there were “great drug companies out there – except for a couple of opioid outfits.”

It's time to rewrite the narrative about Africa's role in the pharmaceutical industry.

Oncology research has come a long way over the past 30 years, but we must transform outdated practices to further improve drug discovery innovation.

How is the changing landscape of microbiome R&D shaping conversations with regulators?

Timo Heikkilä COO at Popit, Finland, explains how technology can help boost patient compliance rates.